News
Noticias
BIAL closes centenary celebrations with a documentary
‘BIAL - 100 Years Inspired by the Future’ will be available on the company’s Youtube channel and RTP Play, with the participation of Paulo Portas, Daniel Bessa, José Aranda da Silva and other leading national figures.
BIAL launches KYNMOBI® in Portugal and Spain
The first sublingual therapy for the on-demand treatment of OFF episodes in Parkinson’s disease
BIAL Announces First Patient Out in its Phase 2 Clinical Trial of BIA 28-6156 - a Novel Therapy for GBA1 Parkinson’s Disease
A hundred-year-old innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, announced that the first patient has completed the full dose regimen in the ACTIVATE Phase 2 study.
BIAL focuses its activity in Mozambique on the commercialisation of medicines
BIAL strengthened the focus of its activity in Mozambique on the commercialisation of medicines
Marcelo Rebelo de Sousa honours BIAL's longest-serving employee in the year of the company’s centenary
President of the Republic visits Portuguese pharmaceutical company's factory as part of the conference celebrating its 100th anniversary
BIAL launches KYNMOBI® in Germany
The first sublingual therapy for the on-demand treatment of OFF episodes in Parkinson’s disease
BIAL appoints Pierluigi Antonelli as Non-Executive Board Member
BIAL appoints Pierluigi Antonelli as Non-Executive Board Member
BIAL celebrates its centenary in 2024
BIAL celebrates its centenary in 2024. Initiatives planned throughout the year will establish relationships with employees, partners and the community.
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)
Amneal and BIAL Announce U.S. Licensing Agreement for ONGENTYS® (opicapone)